Literature DB >> 15523225

Incidence of gastrointestinal cancers in France.

Anne-Marie Bouvier1, Laurent Remontet, Eric Jougla, Guy Launoy, Pascale Grosclaude, Antoine Buémi, Brigitte Tretarre, Michel Velten, Vincent Dancourt, François Menegoz, Anne-Valérie Guizard, Josette Macé Lesec'h, Jung Peng, Paolo Bercelli, Patrick Arveux, Jacques Estève, Jean Faivre.   

Abstract

AIM: Monitoring cancer incidence and time trends is essential for cancer research and health care planning. The aim of the study was to compare the incidence of gastrointestinal cancers in twelve administrative area in France to estimate the national cancer incidence during 2000 compared with the preceding 20 years.
METHODS: Incidence data was provided by cancer registries and mortality data by the French national medical research institute (INSERM). The two data sets were modeled separately over the period 1988-1997 using age-cohort models. The incidence/mortality ratio obtained from these models was applied to the mortality rates of an age-cohort model of the entire population.
RESULTS: The estimated number of new cases of gastrointestinal cancer was 61,465 in 2000. Colorectal cancer was the leading localization with 36,257 cases. The incidence of gastrointestinal cancers was slightly higher in northern than in southern area. Incidence of esophageal cancer was three times that of liver cancer. Variations in incidence were less marked for other localizations. The incidence of gastric and esophageal cancer in the male population decreased between 1980 and 2000, on average by slightly more than 2% per year. Incidence of other cancers increased. The number of new cases of colorectal cancer increased by 50%. The rise in the incidence of liver cancer was particularly striking, with an increase from 2000 incident cases in 1980 to nearly 6000 in 2000.
CONCLUSION: For most localizations, incidence of gastrointestinal cancers displays few geographical differences in France, but there has been a striking change in incidence trends over the past 20 years.

Entities:  

Mesh:

Year:  2004        PMID: 15523225     DOI: 10.1016/s0399-8320(04)95152-4

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  12 in total

1.  Clinical features of colorectal cancer patients in advanced age: a population-based approach.

Authors:  Stefania Maffei; Alessandra Colantoni; Shaniko Kaleci; Piero Benatti; Ester Tesini; Maurizio Ponz de Leon
Journal:  Intern Emerg Med       Date:  2015-10-19       Impact factor: 3.397

2.  An ecological study of cancer incidence and mortality rates in France with respect to latitude, an index for vitamin D production.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2010-04

3.  Impact of liver-directed therapy in colorectal cancer liver metastases.

Authors:  Gabriela M Vargas; Abhishek D Parmar; Kristin M Sheffield; Nina P Tamirisa; Kimberly M Brown; Taylor S Riall
Journal:  J Surg Res       Date:  2014-06-04       Impact factor: 2.192

4.  Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women.

Authors:  Olivier Ganry; B Lapôtre-Ledoux; P Fardellone; A Dubreuil
Journal:  Eur J Epidemiol       Date:  2008-05-10       Impact factor: 8.082

Review 5.  Treatment for colorectal liver metastases: a review.

Authors:  Hiroshi Shimada; Kuniya Tanaka; Itaru Endou; Yasushi Ichikawa
Journal:  Langenbecks Arch Surg       Date:  2009-07-07       Impact factor: 3.445

6.  Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307).

Authors:  Gillles Nuemi; Hervé Devilliers; Karine Le Malicot; Rosine Guimbaud; Côme Lepage; Catherine Quantin
Journal:  Health Qual Life Outcomes       Date:  2015-09-22       Impact factor: 3.186

7.  A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design.

Authors:  Jérémie H Lefevre; Alexandra Rousseau; Magali Svrcek; Yann Parc; Tabassome Simon; Emmanuel Tiret
Journal:  BMC Cancer       Date:  2013-09-12       Impact factor: 4.430

8.  A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.

Authors:  Jean-Baptiste Bachet; Benoist Chibaudel; Franck Bonnetain; Pierre Validire; Pascal Hammel; Thierry André; Christophe Louvet
Journal:  BMC Cancer       Date:  2015-10-06       Impact factor: 4.430

9.  Treatment of pancreatic cancer: what can we really predict today?

Authors:  Jean-Baptiste Bachet; Raphael Marechal; Jean-Luc Van Laethem
Journal:  Cancers (Basel)       Date:  2011-02-17       Impact factor: 6.639

10.  Addition of Molecular Adsorbent Recirculating System (MARS(®)) Albumin Dialysis for the Preoperative Management of Jaundiced Patients with Hilar Cholangiocarcinoma.

Authors:  Jean-Marc Regimbeau; David Fuks; Emilie Chapuis-Roux; Thierry Yzet; Cyril Cosse; Eric Bartoli; Eric N'guyen-Khac; Brice Robert; Eric Lobjoie
Journal:  Case Rep Gastroenterol       Date:  2013-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.